Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.typeArtigo de periódicopt_BR
dc.titleTreatment Of Bone Pain Secondary To Metastases Using Samarium-153-edtmp.pt_BR
dc.contributor.authorEtchebehere, Elba Cristina Sá de Camargopt_BR
dc.contributor.authorPereira Neto, Carlos Araújo Cunhapt_BR
dc.contributor.authorLima, Mariana Cunha Lopes dept_BR
dc.contributor.authorSantos, Allan de Oliveirapt_BR
dc.contributor.authorRamos, Celso Daríopt_BR
dc.contributor.authorSilva, Cleide Mariapt_BR
dc.contributor.authorCamargo, Edwaldo Eduardopt_BR
unicamp.authorElba Cristina Sá de Camargo Etchebehere, Division of Nuclear Medicine, Department of Radiology, and Research Committee, School of Medical Sciences, Universidade Estadual de Campinas (Unicamp), Campinas, São Paulo, Brazil. elba@mn-d.compt_BR Araújo Cunha Pereira Neto,pt Cunha Lopes de Lima,pt de Oliveira Santos,pt Darío Ramos,pt Maria Silva,pt Eduardo Camargo,pt
dc.subjectAnalgesics, Non-narcoticpt_BR
dc.subjectBone Neoplasmspt_BR
dc.subjectDose-response Relationship, Radiationpt_BR
dc.subjectEpidemiologic Methodspt_BR
dc.subjectMiddle Agedpt_BR
dc.subjectOrganometallic Compoundspt_BR
dc.subjectOrganophosphorus Compoundspt_BR
dc.subjectPain Measurementpt_BR
dc.description.abstractMore than 50% of patients with prostate, breast or lung cancer will develop painful bone metastases. The purpose of treating bone metastases is to relieve pain, reduce the use of steroids and to maintain motion. To evaluate the use of samarium-153-EDTMP (153Sm-EDTMP) for the treatment of bone pain secondary to metastases that is refractory to clinical management. Retrospective. Division of Nuclear Medicine, Universidade Estadual de Campinas (Unicamp). Fifty-eight patients were studied (34 males) with mean age 62 years; 31 patients had prostate cancer, 20 had breast cancer, three had lung cancer, one had lung hemangioendothelioma, one had parathyroid adenocarcinoma, one had osteosarcoma and one had an unknown primary tumor. All patients had multiple bone metastases demonstrated by bone scintigraphy using 99mTc-MDP,and were treated with 153Sm-EDTMP. Response to treatment was graded as good (pain reduction of 50-100%), intermediate (25-49%) and poor (0-24%). All patients showed good uptake of 153Sm-EDTMP by bone metastases. Among the patients with prostate cancer, intermediate or good response to therapy occurred in 80.6% (25 patients) and poor response in 19.4% (6). Among the patients with breast cancer, 85% (17) showed intermediate or good response to therapy while 15% (3) showed poor response. All three patients with lung cancer showed poor response to treatment. The lung hemangioendothelioma and unknown primary lesion patients showed intermediate response to treatment; the osteosarcoma and parathyroid adenocarcinoma patients showed good response to treatment. No significant myelotoxicity occurred. Pain control is important for improving the quality of life of patients with advanced cancers. The mechanism by which pain is relieved with the use of radionuclides is still not yet completely understood, however, the treatment is simple and provides a low risk of mielotoxicity. Treatment with 153Sm-EDTMP can control the pain secondary to bone metastases effectively in most patients with breast and prostate cancer without significant side effects.en
dc.relation.ispartofSão Paulo Medical Journal = Revista Paulista De Medicinapt_BR
dc.relation.ispartofabbreviationSao Paulo Med Jpt_BR
dc.identifier.citationSão Paulo Medical Journal = Revista Paulista De Medicina. v. 122, n. 5, p. 208-12, 2004-Sep.pt_BR
dc.description.provenanceMade available in DSpace on 2015-11-27T12:58:36Z (GMT). No. of bitstreams: 1 pmed_15558143.pdf: 792647 bytes, checksum: 66867a1674d3c44d50b6694c76fe41e8 (MD5) Previous issue date: 2004en
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_15558143.pdf774.07 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.